COVID-CANCER HUIL STUDY:Registry of oncologic patients diagnosed with Covid-19 inInfanta Leonor University Hospital in Madrid, Spain

ABSTRACT

Background: Covid-19 has been shown to present more complications in immunosuppressed patients. Wedetermine whether differences exist in Covid-19-related mortality between cancer patients and general population inour hospital, and we also describe associated risk factors. Methods: We reviewed 2,216 medical records of all patients admitted to hospitalization in Infanta Leonor UniversityHospital in Madrid, Spain, with Covid-19 diagnosis between 5 March and 13 May, 2020. Study data were collectedand managed using REDCap electronic data capture tools. We described Covid-19 cumulative incidence in cancerpatients, treatment outcome, mortality, and associated risk factors. Results: We detected 85/2,216 cancer patients between all Covid-19 diagnoses. Mortality rate 40/85 cancerpatients vs. 260/2,131 in general ward (p<0.001). Median age 76 years old (34-94), 50/85 male patients. Mostfrequent histologies were lung cancer (22/85), colorectal cancer (19/85), prostate cancer (15/85), and breast cancer(10/85). Most frequent staging was metastatic disease (32/85). Only 2/85 patients were admitted to ICU. Mortality was associated with older median age (79.5 vs. 73, p=0.03), high d dimer levels (1630 vs. 830, p=0.03), high LDHlevels (315.5 vs. 224, p=0.003), bilateral pneumonia (24/42 vs. 5/22 with unilateral pneumonia, p=0.02), ARDS(12/13 vs. 28/72 without ARDS, p<0.0001), and metastatic disease (20/32 metastatic vs. 20/53 non-metastaticpatients, p=0.02). Differences were maintained in multivariate analyses regarding ARDS (OR 23.7, p=0.007) andmetastatic disease (OR 2.5, p=0.05). Conclusions: Covid-19 had a significant mortality in cancer patients. High D dimer and LDH levels and ARDSdevelopment in elderly metastatic patients carry an elevated risk of death in cancer patients diagnosed with Covid-19. However, only 2/85 patients were admitted to ICU and these data were decisive. It is a priority to createmeasures to avoid Covid-19 transmission in oncologic patients.